Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 4/20 | 0.65 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | THPO | P40225 | 2/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | APEX1 | P27695 | 2/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11534896 | 0.87 | HSD17B10 (0.60) | HSD17B10KDM4EMAPTTDP1HPGD | |
| SCHEMBL23646494 | 0.85 | KDM4E (0.46) | HSD17B10KDM4EMAPTTDP1HPGD | |
| SCHEMBL23646500 | 0.83 | BLM (0.54) | HSD17B10KDM4EMAPTTDP1HPGD | |
| SCHEMBL23646605 | 0.81 | CYP1A2 (0.45) | HSD17B10KDM4EMAPTTDP1HPGD | |
| SCHEMBL12608355 | 0.80 | HSD17B10 (0.48) | HSD17B10KDM4EMAPTTDP1HPGD | |
| SCHEMBL12608299 | 0.80 | MAPT (0.48) | HSD17B10KDM4EMAPTTDP1HPGD | |
| SCHEMBL23646371 | 0.79 | TDP1 (0.42) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL8407333 | 0.79 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL5051647 | 0.79 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTTDP1HPGD | |
| Carbidopa Anhydrous SCHEMBL2688295 | 0.79 | HSD17B10 (1.00) | HSD17B10KDM4EMAPTTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220298-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS | TUFTS MEDICAL CENTER, INC. | 2021-07-22 | — | — | US | claimed |
| US-20210220298-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS | TUFTS MEDICAL CENTER, INC. | 2021-07-22 | — | — | US | disclosed |
| US-4170654-A | Antihypertensive compositions containing N-heterocyclicalanines and α- | MERCK & CO., INC. (US) | 1979-10-09 | — | — | US | disclosed |
| US-4160835-A | Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid | MERCK & CO., INC. (US) | 1979-07-10 | — | — | US | disclosed |
| US-4156734-A | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid | MERCK & CO., INC. (US) | 1979-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220298-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS | GPR119, PC, NLN | HSD17B10 381/4885KDM4E 3272/4885MAPT 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.